ReviewJournal of neuroscience methods2015
α-Synuclein and nonhuman primate models of Parkinson's disease.
Review in Journal of neuroscience methods, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Propagation of α-synuclein pathology: models, mechanisms and future goals.Molecular neurodegeneration advances · 2026Review
- Differential pathological dynamics triggered by distinct Parkinson patient-derived α-synuclein extracts in nonhuman primates.Science advances · 2025Article
- Artificial intelligence in drug development: reshaping the therapeutic landscape.Therapeutic advances in drug safety · 2025Review
- Preclinical evaluation of transaxial intraputaminal trajectory for enhanced distribution of grafted cells in Parkinson's disease.Journal of neurosurgery · 2024Article
- Dopamine-Depleted Dopamine Transporter Knockout (DDD) Mice: Dyskinesia with L-DOPA and Dopamine D1 Agonists.Biomolecules · 2023Article
- Expression of tau and phosphorylated tau in the brain of normal and hemiparkinsonian rhesus macaques.The Journal of comparative neurology · 2023Article
- Parkinson's Disease: Exploring Different Animal Model Systems.International journal of molecular sciences · 2023Review
- α-Synuclein conformers reveal link to clinical heterogeneity of α-synucleinopathies.Translational neurodegeneration · 2023Review
- Article
- Animal models in the study of Alzheimer's disease and Parkinson's disease: A historical perspective.Animal models and experimental medicine · 2022Review
- Alpha-synuclein and tau are abundantly expressed in the ENS of the human appendix and monkey cecum.PloS one · 2022Article
- Parkinson's disease and microRNAs - Lessons from model organisms and human studies.Experimental gerontology · 2021Review
- A New Rise of Non-Human Primate Models of Synucleinopathies.Biomedicines · 2021Review
- Myelin Basic Protein and Cardiac Sympathetic Neurodegeneration in Nonhuman Primates.Neurology research international · 2021Article
- Acute Exposure to the Food-Borne PathogenJournal of inflammation research · 2021Article
- In Vitro CRISPR/Cas9-Directed Gene Editing to Model LRRK2 G2019S Parkinson's Disease in Common Marmosets.Scientific reports · 2020Article
- α-Synuclein Expression Is Preserved in Substantia Nigra GABAergic Fibers of Young and Aged Neurotoxin-Treated Rhesus Monkeys.Cell transplantation · 2019Article
- Colonic inflammation affects myenteric alpha-synuclein in nonhuman primates.Journal of inflammation research · 2019Article
- Non-human primate models of PD to test novel therapies.Journal of neural transmission (Vienna, Austria : 1996) · 2018Review
- α-Synuclein nonhuman primate models of Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Accumulation of α-synuclein (α-syn) leading to the formation of insoluble intracellular aggregates named Lewy bodies is proposed to have a significant role in Parkinson's disease (PD) pathology. Nonhuman primate (NHP) models of PD have proven essential for understanding the neurobiological basis of the disease and for the preclinical evaluation of first-in-class and invasive therapies. In addition to neurotoxin, aging and intracerebral gene transfer models, a new generation of models using inoculations of α-syn formulations, as well as transgenic methods is emerging. Understanding of their advantages and limitations will be essential when choosing a platform to evaluate α-syn-related pathology and interpreting the test results of new treatments targeting α-syn aggregation. In this review we aim to provide insight on this issue by critically analyzing the differences in endogenous α-syn, as well as α-syn pathology in PD and PD NHP models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.